Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
NCT06885814Phase 2Active, not recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective Response Rate at 3 months. Started Jun 2024; status: active, not recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06885814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885814.